NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Hoth Therapeutics, Inc. (HOTH) Stock Analysis

Hoth Therapeutics, Inc. (HOTH) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

HOTH

$0.82

+$0.11 (+15.72%)

Last trade July 17, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HOTH with… →

HOTH Key Statistics

As of Jul 17, 2026
Trading
Open
$0.83
Previous Close
$0.71
Day's Range
0.81–0.85
52-Week Range
0.49–2.12
Volume
580.15K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.58
Valuation
Market Cap
$13.55M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.80
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$12.47M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
−38.86%
Dividend and dates
Avg Volume
2.84M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

HOTH Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−17.24%
2025−47.89%

As of July 17, 2026.

HOTH Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$12.47M—
2024$0.00−$8.19M—
2023$0.00−$8.11M—
2022$0.00−$11.37M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$12.36M−$12.47M—
2024$0.00—−$8.22M−$8.19M—
2023$0.00—−$7.95M−$8.11M—
2022$0.00—−$11.07M−$11.37M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

HOTH Valuation vs Biotechnology Median

Median of 656 stocks
MetricHOTHBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Hoth Therapeutics, Inc. (HOTH) carries a market capitalisation of $13.55M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 2.

The 52-week range on file runs from $0.49 to $2.12. HOTH last closed at $0.82 on July 17, 2026. That is +$0.11 (+15.72%) against the previous close. The latest close sits 67.55% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $12.47M. The reported profit margin is 0%. Trailing earnings per share are −0.8.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the price has returned −38.86%. The stored price history starts on January 10, 2025, and the total return since then is −56.88%. Beta against the wider market is reported at 0.58. Daily returns over the trailing 1 year annualize to a volatility of 83.19%.

Growth & Income

The record shows no dividend for HOTH.

2026 is still running; the price is −17.24% year to date. The record holds one complete calendar year, 2025, which returned −47.89%.

Peer Comparison

Hoth Therapeutics, Inc. (HOTH) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Hoth Therapeutics, Inc. HOTH $13.55M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Hoth Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of July 17, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. The company was incorporated in 2017 and is based in Hoboken, New Jersey.

Visit website →